On March 31, 2023, Cabaletta Bio, Inc., one of IASO Biotherapeutics ("IASO Bio") partners, announced that the Company’s Investigational New Drug (IND) application for CABA-201 has been cleared b...
SAN JOSE, CALIF., NANJING & SHANGHAI, CHINA, February 11, 2023 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing i...
Approaches Commercialization of First Product NANJING & SHANGHAI, CHINA & and SAN JOSE, CALIF., January 18, 2023 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company e...
SHANGHAI, NANJING, China and SAN JOSE, Calif., December xx, 2022 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing inn...
Collaboration will bring together Umoja’s iCIL platform and IASO’s chimeric antigen receptors to create the next generation of broadly accessible, readily available cell therapies in indic...
PHILADELPHIA, Pennsylvania and SAN JOSE, California, NANJING and SHANGHAI, China — October 11, 2022 — IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discove...
SHANGHAI,NANJING,ChinaandSAN JOSE, Calif.,Aug. 19, 2022-- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative c...
SHANGHAI, NANJING, CHINA, AND SAN JOSE , Calif., June 13, 2022 - IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing i...
SHANGHAI, NANJING, CHINA, AND SAN JOSE , Calif., June 2, 2022 - IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing in...
San Jose, CALIF., NANJING & SHANGHAI, CHINA, May 28, 2022 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innova...